Innovation & Development
Utilizing our longstanding experience in the development of parenterally administered generics with medical indication for anti-infective, anesthetic, analgesic and critical care treatment, I&D Graz is substantially contributing to the securement of the Fresenius Kabi global product pipeline and the achievement of corporate strategic goals.
The commitment to highest quality standards as well as dedication, qualification and continuous further education of all our employees depict the basis of our daily development work.
Our development projects are globally oriented and comprise a broad range of activities. Starting with first feasibility trials for the evaluation of new product ideas, continuing with the optimization of the formulation, the development of associated analytical methods and the determination of a suitable primary and secondary packaging system, we provide a finished product ready for commercialization.
In terms of upscaling, we are working closely together with Fresenius Kabi sites all over the world, coordinating these complex transfer projects out of the I&D Graz site as well.
Third party contract development and manufacturing of investigational medicinal products for clinical trial purposes is conducted in our GMP-certified Pilot Plant.
Caring for Life – for us, therapy and supply of critically and chronically ill patients starts with the development of a pharmaceutical drug product. We thus consider it our responsibility to continuously improve our expertise in the areas of pharmaceutical technology and pharmaceutical analytics. Complying with respective regulations, pursuing talent management and maintaining state-of-the-art facilities, instruments and equipment are a fundamental prerequisite for this.